Medication info
Nexium Tablets 20mg (Esomeprazole Magnesium Trihydrate)

Nexium Tablets 20mg (Esomeprazole Magnesium Trihydrate)

Prescription medicationTabletOral · Intravenous injection
Ingredient · strength
Esomeprazole Magnesium Dihydrate›21.69mg / 1 tablet
Manufacturer / importer
CL Pharm Co., Ltd.
Appearance
Pink round film-coated tablet
Packaging
28 tablets/box [(14 tablets/Alu-Alu) x 2]
Approval status
Active

MFDS item code 201602266 · Approved 2016.04.22 · Insurance code 622600280

Summary

Main use
Treatment and prevention of acid-related disorders, ulcers, and rebleeding; Helicobacter pylori eradication; relief of symptoms caused by anti-inflammatory analgesics
Who uses it
Adults · Children
Adult dosage
1) Gastroesophageal reflux disease (GERD). - Treatment of erosive reflux esophagitis: Administer 40 mg once daily for 4 weeks. If esophagitis has not healed or symptoms persist, continue treatment for an additional 4 weeks. - Long-term maintenance therapy to prevent recurrence in patients with esophagitis: 20 mg once daily - Symptomatic treatment of gastroesophageal reflux disease without esophagitis: · 20 mg once daily. If symptoms are not controlled after 4 weeks, further evaluation is required. · Once symptoms have resolved, subsequent recurring symptoms are controlled by administering 20 mg once daily. · In adults, 20 mg may be administered once daily as needed. As-needed use to control recurring symptoms is not recommended in patients at high risk of developing gastric and duodenal ulcers due to NSAID use. 2) Combination therapy with antibiotics for Helicobacter pylori eradication Administer this medicine 20 mg with amoxicillin 1 g and clarithromycin 500 mg twice daily for 7 days. 3) Short-term treatment of upper gastrointestinal symptoms (pain, discomfort, burning sensation) associated with NSAID (nonselective or selective COX-2 inhibitor) use - 20 mg once daily. If symptoms are not controlled after 4 weeks, further evaluation is required. Clinical trials extending beyond 4 weeks have not been conducted. 4) Patients requiring continuous NSAID treatment - Treatment of gastric ulcers associated with NSAID use: 20 mg once daily. The treatment period is 4∼8 weeks. - Prevention of gastric and duodenal ulcers associated with NSAID use: 20 mg once daily. 5) Treatment of Zollinger-Ellison syndrome The recommended initial dose is 40 mg twice daily. The dose should then be adjusted for each patient, and treatment should continue for as long as clinical symptoms are present. Clinical data indicate that most patients can be controlled with doses of 80 ∼ 160 mg per day. Doses above 80 mg per day should be divided into two doses. 6) Maintenance therapy following induction of prevention of rebleeding from gastric or duodenal ulcers by intravenous injection Administer 40 mg once daily for 4 weeks following induction of prevention of rebleeding from gastric or duodenal ulcers by intravenous injection. 4. Renal impairment No dose adjustment is necessary. Use with caution because experience administering this medicine to patients with severe renal impairment is limited. 5. Hepatic impairment No dose adjustment is necessary in patients with mild to moderate hepatic impairment. In patients with severe hepatic impairment, the dose of this medicine must not exceed 20 mg. 6. Older adults No dose adjustment is necessary.
Children's dosage
2. Adolescents aged 12 years and older 1) Gastroesophageal reflux disease (GERD) - Treatment of erosive reflux esophagitis: Administer 40 mg once daily for 4 weeks. If esophagitis has not healed or symptoms persist, continue treatment for an additional 4 weeks. - Symptomatic treatment of gastroesophageal reflux disease without esophagitis: · 20 mg once daily. If symptoms are not controlled after 4 weeks, further evaluation is required. · Once symptoms have resolved, subsequent recurring symptoms are controlled by administering 20 mg once daily. · In adults, 20 mg may be administered once daily as needed. As-needed use to control recurring symptoms is not recommended in patients at high risk of developing gastric and duodenal ulcers due to NSAID use. 3. Children under 12 years of age There is no experience with administration of this medicine to children under 12 years of age.

Ingredients

Manufacturer
CL Pharm Co., Ltd.

Efficacy & effects

Treatment and prevention of acid-related disorders, ulcers, and rebleeding; Helicobacter pylori eradication; relief of symptoms caused by anti-inflammatory analgesics

  • Gastroesophageal reflux disease
  • reflux esophagitis
  • esophagitis
  • duodenal ulcers
  • peptic ulcers
  • upper gastrointestinal pain
  • upper gastrointestinal discomfort
  • upper gastrointestinal burning sensation
  • gastric ulcers
  • duodenal ulcers
  • Zollinger-Ellison syndrome
  • gastric ulcer rebleeding
View approved original text

This medication is used for the treatment of gastroesophageal reflux disease and reflux esophagitis, and it is also effective for long-term maintenance therapy to prevent recurrence. It helps in treating and preventing recurrence of duodenal ulcers and peptic ulcers associated with Helicobacter pylori infection. It is also used to treat and prevent upper gastrointestinal symptoms such as gastric ulcers and duodenal ulcers due to non-steroidal anti-inflammatory analgesics. Additionally, it is applicable for the treatment of Zollinger-Ellison syndrome and maintenance therapy after prevention of rebleeding from gastric or duodenal ulcers. Overall, it is effectively used for the treatment and prevention of gastrointestinal-related diseases.

Dosage and Administration

Adult dosage

1) Gastroesophageal reflux disease (GERD). - Treatment of erosive reflux esophagitis: Administer 40 mg once daily for 4 weeks. If esophagitis has not healed or symptoms persist, continue treatment for an additional 4 weeks. - Long-term maintenance therapy to prevent recurrence in patients with esophagitis: 20 mg once daily - Symptomatic treatment of gastroesophageal reflux disease without esophagitis: · 20 mg once daily. If symptoms are not controlled after 4 weeks, further evaluation is required. · Once symptoms have resolved, subsequent recurring symptoms are controlled by administering 20 mg once daily. · In adults, 20 mg may be administered once daily as needed. As-needed use to control recurring symptoms is not recommended in patients at high risk of developing gastric and duodenal ulcers due to NSAID use. 2) Combination therapy with antibiotics for Helicobacter pylori eradication Administer this medicine 20 mg with amoxicillin 1 g and clarithromycin 500 mg twice daily for 7 days. 3) Short-term treatment of upper gastrointestinal symptoms (pain, discomfort, burning sensation) associated with NSAID (nonselective or selective COX-2 inhibitor) use - 20 mg once daily. If symptoms are not controlled after 4 weeks, further evaluation is required. Clinical trials extending beyond 4 weeks have not been conducted. 4) Patients requiring continuous NSAID treatment - Treatment of gastric ulcers associated with NSAID use: 20 mg once daily. The treatment period is 4∼8 weeks. - Prevention of gastric and duodenal ulcers associated with NSAID use: 20 mg once daily. 5) Treatment of Zollinger-Ellison syndrome The recommended initial dose is 40 mg twice daily. The dose should then be adjusted for each patient, and treatment should continue for as long as clinical symptoms are present. Clinical data indicate that most patients can be controlled with doses of 80 ∼ 160 mg per day. Doses above 80 mg per day should be divided into two doses. 6) Maintenance therapy following induction of prevention of rebleeding from gastric or duodenal ulcers by intravenous injection Administer 40 mg once daily for 4 weeks following induction of prevention of rebleeding from gastric or duodenal ulcers by intravenous injection. 4. Renal impairment No dose adjustment is necessary. Use with caution because experience administering this medicine to patients with severe renal impairment is limited. 5. Hepatic impairment No dose adjustment is necessary in patients with mild to moderate hepatic impairment. In patients with severe hepatic impairment, the dose of this medicine must not exceed 20 mg. 6. Older adults No dose adjustment is necessary.

Children's dosage

2. Adolescents aged 12 years and older 1) Gastroesophageal reflux disease (GERD) - Treatment of erosive reflux esophagitis: Administer 40 mg once daily for 4 weeks. If esophagitis has not healed or symptoms persist, continue treatment for an additional 4 weeks. - Symptomatic treatment of gastroesophageal reflux disease without esophagitis: · 20 mg once daily. If symptoms are not controlled after 4 weeks, further evaluation is required. · Once symptoms have resolved, subsequent recurring symptoms are controlled by administering 20 mg once daily. · In adults, 20 mg may be administered once daily as needed. As-needed use to control recurring symptoms is not recommended in patients at high risk of developing gastric and duodenal ulcers due to NSAID use. 3. Children under 12 years of age There is no experience with administration of this medicine to children under 12 years of age.

Precautions

This medication should not be administered to certain patients. Those with hypersensitivity to this drug, its components, or benzimidazole class drugs should not use it. Caution is also needed for those allergic to penicillin antibiotics or macrolide antibiotics during combination therapy. Patients taking certain heart-related medications or antivirals, as well as lactating women, should not use this drug. Various adverse reactions can occur with this medication. Commonly, headaches, abdominal pain, diarrhea, constipation, nausea, and vomiting may occur; and rarely blood disorders, hypomagnesemia, confusion, skin rashes, and liver function abnormalities have been reported. In severe cases, serious skin reactions or muscle problems, interstitial nephritis, may develop, and any symptoms should lead to immediate consultation with healthcare professionals. Long-term use of this medication might mask symptoms of malignant tumors, so a medical diagnosis is mandatory if any symptoms seem suspicious. Regular checks are necessary for use exceeding one year, and any changes in symptoms should prompt immediate consultation with healthcare professionals. This medication reduces gastric acid, increasing the risk of bacterial overgrowth in the gastrointestinal tract; therefore, if diarrhea symptoms persist, it should be checked for infection. Patients with osteoporosis or high fracture risk should exercise caution when using this medication at high doses for prolonged periods due to increased fracture risk. Additionally, hypomagnesemia may occur, so magnesium levels should be regularly checked during prolonged use or when combined with certain drugs. This medication has many interactions with other drugs, which can alter its effects or increase the risk of side effects depending on the medications taken concurrently. Caution is advised especially when used with anticoagulants, antibiotics, antivirals, or anticonvulsants, and adjustments may be necessary after consultation with a physician or pharmacist. The safety of this drug during pregnancy has not been sufficiently confirmed; hence careful prescription is advisable for pregnant women, and it is recommended that lactating women refrain from taking this medication. In case of overdose, since there is no specific antidote, treatment should be symptomatic and general management should be provided. This medication should be kept out of the reach of children and it is safer not to transfer it to other containers.

Side effects

Leukopenia, thrombocytopenia, agranulocytosis, pancytopenia, fever, angioedema, anaphylactic reaction, shock, peripheral edema, hyponatremia, hypomagnesemia, insomnia, anxiety, mental confusion, depression, aggression, hallucinations, headache, dizziness, paresthesia, drowsiness, taste disturbance, blurred vision, bronchospasm, pancreatitis, abdominal pain, constipation, diarrhea, abdominal bloating, nausea, vomiting, dry mouth, stomatitis, gastrointestinal candidiasis, microscopic colitis, increased liver enzymes, jaundice, hepatitis, liver failure, encephalopathy, dermatitis, itching, rash, urticaria, hair loss, photosensitivity, erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis, Lille syndrome, acute generalized exanthematous pustulosis, drug reaction with eosinophilia and systemic symptoms, fracture, arthralgia, myalgia, muscle weakness, interstitial nephritis, gynecomastia, asthenia, increased sweating, Clostridium difficile-associated diarrhea, abdominal distension, allergic reaction, back pain, chest pain, substernal pain, facial edema, facial flushing, fatigue, fever, influenza-like illness, generalized edema, leg edema, malaise, pain, stiffness, anemia, hypopigmented anemia, cervical lymphadenopathy, epistaxis, leukocytosis, leukopenia, thrombocytopenia, hyperbilirubinemia, abnormal liver function, increased ALT, increased AST, diabetes, hyperuricemia, increased ALP, dry mouth, vitamin B12 deficiency, weight gain, weight loss, exacerbation of arthritis, arthropathy, convulsions, fibromyalgia syndrome, hernia, polymyalgia rheumatica, anorexia, apathy, increased appetite, confusion, worsening depression, hypertonicity, sensory loss, erectile dysfunction, insomnia, migraine, exacerbation of migraine, sleep disorders, tremor, visual field defect, dysmenorrhea, menstrual disorders, vaginitis, exacerbation of asthma, cough, dyspnea, laryngeal edema, pharyngitis, rhinitis, sinusitis, acne, anal itching, erythematous rash, papular rash, otitis media, altered smell, taste loss, taste disorder, abnormal urine, albuminuria, cystitis, dysuria, fungal infection, hematuria, urinary frequency, candidiasis, genital candidiasis, polyuria, conjunctivitis, visual disturbances, duodenitis, esophagitis, esophageal stricture, esophageal ulcer, esophageal varices, gastric ulcer, gastritis, benign polyp or nodule, Barrett's esophagus, mucosal discoloration, hernia, systemic lupus erythematosus, cutaneous lupus erythematosus, hypocalcemia, hypokalemia, rhabdomyolysis

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to prevent exposure to air and moisture and should be kept at room temperature between 1°C and 30°C. This storage helps maintain the drug's effectiveness.

Appearance and packaging

Appearance

Pink round film-coated tablet

Package unit

28 tablets/box [(14 tablets/Alu-Alu) x 2]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.